Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies

详细信息    查看全文

• 作者：Orly R. Klein¹ ; ^{oklein2@jhmi.edu} ; Jessica Buddenbaum² ; Noah Tucker² ; Allen R. Chen¹ ; Christopher J. Gamper¹ ; David Loeb¹ ; Elias Zambidis¹ ; Nicolas J. Llosa¹ ; Jeffrey S. Huo¹ ; Nancy Robey¹ ; Mary Jo Holuba¹ ; Yvette L. Kasamon³ ; Shannon R. McCurdy³ ; Richard Ambinder³ ; Javier Bolañ ; os-Meade³ ; Leo Luznik³ ; Ephraim J. Fuchs³ ; Richard J. Jones³ ; Kenneth R. Cooke¹ ; Heather J. Symons¹
• 关键词：HLA-haploidentical transplantation ; Cyclophosphamide ; Nonmyeloablative bone marrow transplantation ; Acute leukemia ; Lymphoma ; Myelodysplastic syndrome
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：23
• 期：2
• 页码：325-332
• 全文大小：1032 K
• 卷排序：23

文摘

Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide in pediatric patients with high-risk hematologic malignancies is a safe and effective treatment Outcomes for pediatric and young adult patients are comparable to published adult outcomes